Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.77)
# 771
Out of 4,711 analysts
428
Total ratings
45.81%
Success rate
9.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $63 | $15.48 | +306.98% | 25 | Dec 17, 2024 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $12 | $0.83 | +1,354.55% | 14 | Dec 10, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Neutral | $7.5 | $5.86 | +27.99% | 11 | Dec 4, 2024 | |
| AKRO Akero Therapeutics | Reiterates: Buy | $50 | $29.34 | +70.42% | 22 | Nov 18, 2024 | |
| ABUS Arbutus Biopharma | Reiterates: Buy | $5 | $3.21 | +55.76% | 17 | Nov 18, 2024 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $32 | $4.95 | +546.46% | 9 | Nov 15, 2024 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $11 | $1.04 | +957.69% | 15 | Nov 15, 2024 | |
| UNCY Unicycive Therapeutics | Maintains: Buy | $2.5 → $4 | $0.68 | +484.80% | 23 | Nov 14, 2024 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.95 | - | 12 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Buy | $66 | $41.51 | +59.00% | 29 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $23.22 | +3.36% | 21 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $7.94 | +265.24% | 20 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5.5 | $4.82 | +14.11% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $13.21 | +187.66% | 20 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $39.84 | +88.25% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $95 | $44.22 | +114.83% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $1.83 | +309.84% | 32 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $390 | $308.44 | +26.44% | 15 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $2.35 | +453.19% | 13 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.80 | +242.11% | 17 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $6.28 | +329.94% | 9 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $18 | $17.18 | +4.77% | 19 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $15.21 | - | 6 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.77 | +182.49% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $9.03 | +43.96% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.64 | +844.44% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $1.14 | +20,952.63% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.42 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $42.60 | -41.31% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.05 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.87 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13,500 → $14,625 | $1.77 | +826,171.19% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $42.25 | -83.43% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.70 | -29.29% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.19 | - | 2 | Feb 15, 2017 |
Arcturus Therapeutics Holdings
Dec 17, 2024
Reiterates: Buy
Price Target: $63
Current: $15.48
Upside: +306.98%
Acurx Pharmaceuticals
Dec 10, 2024
Reiterates: Buy
Price Target: $12
Current: $0.83
Upside: +1,354.55%
Terns Pharmaceuticals
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $5.86
Upside: +27.99%
Akero Therapeutics
Nov 18, 2024
Reiterates: Buy
Price Target: $50
Current: $29.34
Upside: +70.42%
Arbutus Biopharma
Nov 18, 2024
Reiterates: Buy
Price Target: $5
Current: $3.21
Upside: +55.76%
Sagimet Biosciences
Nov 15, 2024
Reiterates: Buy
Price Target: $32
Current: $4.95
Upside: +546.46%
Galectin Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $11
Current: $1.04
Upside: +957.69%
Unicycive Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $2.5 → $4
Current: $0.68
Upside: +484.80%
DURECT
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.95
Upside: -
Mirum Pharmaceuticals
Nov 13, 2024
Reiterates: Buy
Price Target: $66
Current: $41.51
Upside: +59.00%
Nov 11, 2024
Reiterates: Buy
Price Target: $24
Current: $23.22
Upside: +3.36%
Nov 11, 2024
Reiterates: Buy
Price Target: $29
Current: $7.94
Upside: +265.24%
Nov 11, 2024
Downgrades: Neutral
Price Target: $5.5
Current: $4.82
Upside: +14.11%
Nov 8, 2024
Reiterates: Buy
Price Target: $38
Current: $13.21
Upside: +187.66%
Nov 7, 2024
Reiterates: Buy
Price Target: $75
Current: $39.84
Upside: +88.25%
Nov 6, 2024
Maintains: Buy
Price Target: $82 → $95
Current: $44.22
Upside: +114.83%
Oct 23, 2024
Reiterates: Buy
Price Target: $7.5
Current: $1.83
Upside: +309.84%
Oct 22, 2024
Reiterates: Buy
Price Target: $390
Current: $308.44
Upside: +26.44%
Oct 15, 2024
Maintains: Buy
Price Target: $14 → $13
Current: $2.35
Upside: +453.19%
Oct 11, 2024
Reiterates: Buy
Price Target: $13
Current: $3.80
Upside: +242.11%
Oct 10, 2024
Reiterates: Buy
Price Target: $27
Current: $6.28
Upside: +329.94%
Sep 27, 2024
Maintains: Buy
Price Target: $23 → $18
Current: $17.18
Upside: +4.77%
Sep 24, 2024
Reiterates: Neutral
Price Target: n/a
Current: $15.21
Upside: -
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.77
Upside: +182.49%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $9.03
Upside: +43.96%
Aug 16, 2024
Reiterates: Buy
Price Target: $6
Current: $0.64
Upside: +844.44%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $1.14
Upside: +20,952.63%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $42.60
Upside: -41.31%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.05
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.87
Upside: -
May 12, 2020
Maintains: Buy
Price Target: $13,500 → $14,625
Current: $1.77
Upside: +826,171.19%
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $42.25
Upside: -83.43%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.70
Upside: -29.29%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.19
Upside: -